Clinical Trials
8 trialsNCT04452877 2026-01-13
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC
Novartis
Phase 2 Completed
NCT03299088 2025-05-21
Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations
University of California, Davis
Phase 1 Completed
NCT03704688 2025-05-16
Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT04967079 2024-04-23
Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients
Shanghai Chest Hospital
Phase 1 Completed
NCT01336634 2022-04-04
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
Novartis
Phase 2 Completed
NCT02900664 2022-03-29
A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)
Novartis
Phase 1 Completed
NCT01324258 2017-11-13
Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT01362296 2014-07-11
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Completed